241-255 of 305
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
- advertisement
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®Insights from global key opinion leaders on optimizing patient care in NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CEEmpowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Joyce O'Shaughnessy, MD
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CEBringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
David H. Ilson, MD, PhD
Sunnie Kim, MD
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
- advertisement
- MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®Treatment Intensification in HR+/HER2- EBC: Who and When?
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
